Physician profile
Kenneth E Locklear
NPI 1275530594
$2,830.52
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $876 · 2020: $718 · 2021: $1,101 · 2022: $115 · 2024: $20.46.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $20.46.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $20.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $470.35 | 2019-2022 | |
| Glaxosmithkline, LLC. | $331.38 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $255.23 | 2019-2021 | |
| Novo Nordisk INC | $169.30 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $165.93 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $162.34 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $145.94 | 2019-2022 | |
| Abbvie INC. | $125.21 | 2021 | |
| Sunovion Pharmaceuticals INC. | $113.53 | 2019-2020 | |
| Amarin Pharma, INC. | $111.23 | 2019-2021 | |
| Mylan Specialty L.P. | $98.94 | 2019-2020 | |
| Pfizer INC. | $87.17 | 2019-2021 | |
| Scilex Pharmaceuticals INC. | $71.73 | 2019-2021 | |
| Esperion Therapeutics, INC. | $64.32 | 2021 | |
| Lilly USA, LLC | $62.79 | 2021-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $53.14 | 2020-2021 | |
| Hikma Pharmaceuticals USA | $47.65 | 2019-2021 | |
| Allergan, INC. | $40.96 | 2019 | |
| Sanofi-Aventis U.S. LLC | $38.51 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $32.08 | 2019 | |
| Eyevance Pharmaceuticals LLC | $29.55 | 2021 | |
| Eisai INC. | $26.40 | 2020 | |
| Amgen INC. | $24.41 | 2019-2020 | |
| Biogen, INC. | $22.61 | 2020-2021 | |
| Lundbeck LLC | $20.46 | 2024 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $18.14 | 2021 | |
| Ironwood Pharmaceuticals, INC | $14.58 | 2019 | |
| Neotract INC. | $13.53 | 2019 | |
| Strongbridge US INC. | $13.11 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Locklear listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.